Monitor filing of the resale registration statement, which could increase share float and near-term trading pressure. Watch for warrant exercise activity, which would bring in additional capital but further dilute shareholders.
Price Chart
Executive Summary
Artelo Biosciences announced a private placement of 3,188,407 shares (or pre-funded warrants) and accompanying warrants to raise approximately $11.0 million in gross proceeds, with potential additional proceeds of $20.4 million if all warrants are exercised. The funds will be used for working capital, general corporate purposes, and repayment of bridge debt.
Key Financial Metrics
Key Facts
- Private placement of 3,188,407 shares or pre-funded warrants and warrants for up to 6,376,814 shares
- Combined purchase price of $3.45 per share and accompanying warrant
- Warrants exercisable immediately at $3.20 per share, expiring 5.5 years from effectiveness date
- Gross proceeds expected to be $11.0 million, with potential additional $20.4 million if warrants are fully exercised
- Proceeds to be used for working capital, general corporate purposes, and repayment of certain bridge debt
- H.C. Wainwright & Co. acting as exclusive placement agent
- Offering exempt under Section 4(a)(2) and Regulation D; resale registration to be filed
Financial Impact
$11.0 million in immediate gross proceeds, with up to $20.4 million in potential future proceeds if warrants are exercised
Risk Factors
- Significant dilution from both the issuance of new shares and potential exercise of warrants
- No assurance that warrants will be exercised, leaving future funding needs uncertain
- Use of proceeds includes repayment of bridge debt, which may indicate prior liquidity pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263855 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $3.11 | awaiting T+60 | — | $2.20 (+29.26%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.20 (−41.33%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.20 (−67.79%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.20 (+109.52%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.20 (−98.20%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.20 (−50.68%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.20 (+61.76%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.20 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers